139 related articles for article (PubMed ID: 35676195)
21. Long-term adverse event profile from four completed trials of oral eliglustat in adults with Gaucher disease type 1.
Peterschmitt MJ; Freisens S; Underhill LH; Foster MC; Lewis G; Gaemers SJM
Orphanet J Rare Dis; 2019 Jun; 14(1):128. PubMed ID: 31174576
[TBL] [Abstract][Full Text] [Related]
22. Gaucher disease and its treatment options.
Bennett LL; Mohan D
Ann Pharmacother; 2013 Sep; 47(9):1182-93. PubMed ID: 24259734
[TBL] [Abstract][Full Text] [Related]
23. Eliglustat compared with imiglucerase in patients with Gaucher's disease type 1 stabilised on enzyme replacement therapy: a phase 3, randomised, open-label, non-inferiority trial.
Cox TM; Drelichman G; Cravo R; Balwani M; Burrow TA; Martins AM; Lukina E; Rosenbloom B; Ross L; Angell J; Puga AC
Lancet; 2015 Jun; 385(9985):2355-62. PubMed ID: 25819691
[TBL] [Abstract][Full Text] [Related]
24. Combined miglustat and enzyme replacement therapy in two patients with type 1 Gaucher disease: two case reports.
Amato D; Patterson MA
J Med Case Rep; 2018 Jan; 12(1):19. PubMed ID: 29373994
[TBL] [Abstract][Full Text] [Related]
25. Outcomes after 18 months of eliglustat therapy in treatment-naïve adults with Gaucher disease type 1: The phase 3 ENGAGE trial.
Mistry PK; Lukina E; Ben Turkia H; Shankar SP; Baris H; Ghosn M; Mehta A; Packman S; Pastores G; Petakov M; Assouline S; Balwani M; Danda S; Hadjiev E; Ortega A; Gaemers SJM; Tayag R; Peterschmitt MJ
Am J Hematol; 2017 Nov; 92(11):1170-1176. PubMed ID: 28762527
[TBL] [Abstract][Full Text] [Related]
26. A phase 2 study of eliglustat tartrate (Genz-112638), an oral substrate reduction therapy for Gaucher disease type 1.
Lukina E; Watman N; Arreguin EA; Banikazemi M; Dragosky M; Iastrebner M; Rosenbaum H; Phillips M; Pastores GM; Rosenthal DI; Kaper M; Singh T; Puga AC; Bonate PL; Peterschmitt MJ
Blood; 2010 Aug; 116(6):893-9. PubMed ID: 20439622
[TBL] [Abstract][Full Text] [Related]
27. Successful switch from enzyme replacement therapy to miglustat in an adult patient with type 1 Gaucher disease: a case report.
Giuffrida G; Lombardo R; Di Francesco E; Parrinello L; Di Raimondo F; Fiumara A
J Med Case Rep; 2016 Nov; 10(1):315. PubMed ID: 27821156
[TBL] [Abstract][Full Text] [Related]
28. Once- versus twice-daily dosing of eliglustat in adults with Gaucher disease type 1: The Phase 3, randomized, double-blind EDGE trial.
Charrow J; Fraga C; Gu X; Ida H; Longo N; Lukina E; Nonino A; Gaemers SJM; Jouvin MH; Li J; Wu Y; Xue Y; Peterschmitt MJ
Mol Genet Metab; 2018 Mar; 123(3):347-356. PubMed ID: 29358012
[TBL] [Abstract][Full Text] [Related]
29. A pooled analysis of adverse events in 393 adults with Gaucher disease type 1 from four clinical trials of oral eliglustat: Evaluation of frequency, timing, and duration.
Peterschmitt MJ; Cox GF; Ibrahim J; MacDougall J; Underhill LH; Patel P; Gaemers SJM
Blood Cells Mol Dis; 2018 Feb; 68():185-191. PubMed ID: 28126395
[TBL] [Abstract][Full Text] [Related]
30. Safety and efficacy of eliglustat combined to enzyme replacement therapy for lymphadenopathy in patients with Gaucher disease type 3.
Lee NC; Chien YH; Wang CH; Wong SL; Peng SS; Tsai FJ; Hwu WL
Mol Genet Metab Rep; 2022 Jun; 31():100867. PubMed ID: 35782609
[TBL] [Abstract][Full Text] [Related]
31. Stability is maintained in adults with Gaucher disease type 1 switched from velaglucerase alfa to eliglustat or imiglucerase: A sub-analysis of the eliglustat ENCORE trial.
Pleat R; Cox TM; Burrow TA; Giraldo P; Goker-Alpan O; Rosenbloom BE; Croal LR; Underhill LH; Gaemers SJ; Peterschmitt MJ
Mol Genet Metab Rep; 2016 Dec; 9():25-28. PubMed ID: 27722092
[TBL] [Abstract][Full Text] [Related]
32. Profile of eliglustat tartrate in the management of Gaucher disease.
Sechi A; Dardis A; Bembi B
Ther Clin Risk Manag; 2016; 12():53-8. PubMed ID: 26811686
[TBL] [Abstract][Full Text] [Related]
33. Type 1 Gaucher disease (CYP2D6-eliglustat).
Becquemont L
Therapie; 2017 Apr; 72(2):323-326. PubMed ID: 28242126
[TBL] [Abstract][Full Text] [Related]
34. Real life data: follow-up assessment on Spanish Gaucher disease patients treated with eliglustat. TRAZELGA project.
Serrano-Gonzalo I; de Frutos LL; Lahoz-Gil C; Delgado-Mateos F; Fernández-Galán MÁ; Morales-Conejo M; Calle-Gordo MV; Ibarretxe-Gerediaga D; Madinaveitia-Ochoa A; Albarracin-Arraigosa A; Balanzat-Muñoz J; Correcher-Medina P; García-Frade LJ; Hernández-Rivas JM; Labbadia F; López-Dupla JM; Lozano-Almela ML; Mora-Casterá E; Noya-Pereira MS; Ruíz-Guinaldo MÁ; Del Mar Tormo-Díaz M; Vitoria-Miñana I; Arévalo-Vargas I; Andrade-Campos M; Giraldo P
Orphanet J Rare Dis; 2023 Dec; 18(1):390. PubMed ID: 38102667
[TBL] [Abstract][Full Text] [Related]
35. Suicidal attempt with eliglustat overdose.
Nadler J; Hermanns-Clausen M; Dilger K
JIMD Rep; 2023 Jan; 64(1):23-26. PubMed ID: 36636596
[TBL] [Abstract][Full Text] [Related]
36. Combination therapy in a patient with chronic neuronopathic Gaucher disease: a case report.
Ceravolo F; Grisolia M; Sestito S; Falvo F; Moricca MT; Concolino D
J Med Case Rep; 2017 Jan; 11(1):19. PubMed ID: 28103924
[TBL] [Abstract][Full Text] [Related]
37. Miglustat (Zavesca) in type 1 Gaucher disease: 5-year results of a post-authorisation safety surveillance programme.
Hollak CE; Hughes D; van Schaik IN; Schwierin B; Bembi B
Pharmacoepidemiol Drug Saf; 2009 Sep; 18(9):770-7. PubMed ID: 19507165
[TBL] [Abstract][Full Text] [Related]
38. Eliglustat tartrate, a prototypic glucosylceramide synthase inhibitor.
Shayman JA
Expert Rev Endocrinol Metab; 2013 Nov; 8(6):491-504. PubMed ID: 30736134
[TBL] [Abstract][Full Text] [Related]
39. Oral maintenance clinical trial with miglustat for type I Gaucher disease: switch from or combination with intravenous enzyme replacement.
Elstein D; Dweck A; Attias D; Hadas-Halpern I; Zevin S; Altarescu G; Aerts JF; van Weely S; Zimran A
Blood; 2007 Oct; 110(7):2296-301. PubMed ID: 17609429
[TBL] [Abstract][Full Text] [Related]
40. Impact of hepatic and renal impairment on the pharmacokinetics and tolerability of eliglustat therapy for Gaucher disease type 1.
Li J; Chen J; Kanamaluru V; Gaemers SJM; Peterschmitt MJ; Hou AW; Xue Y; Turpault S; Rudin D
Mol Genet Metab; 2020 Feb; 129(2):117-124. PubMed ID: 31924461
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
